MedPath

Guaifenesin

GUAIFENESIN EXTENDED-RELEASE TABLETS

Approved
Approval ID

038e1801-b978-4a2e-ae8c-8803596ec09c

Product Type

HUMAN OTC DRUG LABEL

Effective Date

May 20, 2025

Manufacturers
FDA

PUBLIX SUPER MARKETS, INC

DUNS: 006922009

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Guaifenesin

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code41415-997
Application NumberANDA209254
Product Classification
M
Marketing Category
C73584
G
Generic Name
Guaifenesin
Product Specifications
Route of AdministrationORAL
Effective DateMay 20, 2025
FDA Product Classification

INGREDIENTS (6)

HYPROMELLOSE, UNSPECIFIEDInactive
Code: 3NXW29V3WO
Classification: IACT
MAGNESIUM STEARATEInactive
Code: 70097M6I30
Classification: IACT
SILICON DIOXIDEInactive
Code: ETJ7Z6XBU4
Classification: IACT
FD&C BLUE NO. 2Inactive
Code: L06K8R7DQK
Classification: IACT
POVIDONE, UNSPECIFIEDInactive
Code: FZ989GH94E
Classification: IACT
GUAIFENESINActive
Quantity: 1200 mg in 1 1
Code: 495W7451VQ
Classification: ACTIB

Drug Labeling Information

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

LOINC: 51945-4Updated: 2/11/2022

PRINCIPAL DISPLAY PANEL - 1200 mg Extended-Release Tablet Blister Pack

Carton

NDC 41415-997-14

12-HOUR MAXIMUM STRENGTH
mucusrelief
GUAIFENESIN EXTENDED-RELEASE
TABLETS, 1200 mg
EXPECTORANT

12 Hour

  • Relieves Chest Congestion
  • Thins and Loosens Mucus

14
EXTENDED-RELEASE
TABLETS

†Compare to the active
ingredient of Mucinex ®
Maximum Strength

![publix-1200mg-spl-1](/dailymed/image.cfm?name=publix-1200mg- spl-1.jpg&id=875969)

![publix-1200mg-spl-2](/dailymed/image.cfm?name=publix-1200mg- spl-2.jpg&id=875969)

INDICATIONS & USAGE SECTION

LOINC: 34067-9Updated: 2/9/2022

Uses

helps loosen phlegm (mucus) and thin bronchial secretions to rid the bronchial passageways of bothersome mucus and make coughs more productive

SPL UNCLASSIFIED SECTION

LOINC: 42229-5Updated: 2/9/2022

DISTRIBUTED BY PUBLIX SUPER MARKETS, INC.,
** 3300 PUBLIX CORPORATE PARKWAY**
** LAKELAND, FL 33811**

OTC - ACTIVE INGREDIENT SECTION

LOINC: 55106-9Updated: 2/9/2022

Active ingredient (in each extended-release tablet)

Guaifenesin, USP 1200 mg

OTC - PURPOSE SECTION

LOINC: 55105-1Updated: 2/9/2022

Purpose

Expectorant

WARNINGS SECTION

LOINC: 34071-1Updated: 2/9/2022

Warnings

Do not use

  • for children under 12 years of age

Ask a doctor before use if you have

  • persistent or chronic cough such as occurs with smoking, asthma, chronic bronchitis, or emphysema
  • cough accompanied by too much phlegm (mucus)

Stop use and ask a doctor if

  • cough lasts more than 7 days, comes back, or occurs with fever, rash, or persistent headache.
    These could be signs of a serious illness.

**If pregnant or breast-feeding,**ask a health professional before use.

Keep out of reach of children.

In case of overdose, get medical help or contact a Poison Control Center right away (1-800-222-1222).

DOSAGE & ADMINISTRATION SECTION

LOINC: 34068-7Updated: 2/9/2022

Directions

  • do not crush, chew, or break extended-release tablet
  • take with a full glass of water
  • this product can be administered without regard for the timing of meals
  • adults and children 12 years of age and over: 1 extended-release tablet every 12 hours. Do not exceed 2 extended-release tablets in 24 hours.
  • children under 12 years of age: do not use

STORAGE AND HANDLING SECTION

LOINC: 44425-7Updated: 2/11/2022

Other information

  • store between 68-77°F (20-25°C) *TAMPER EVIDENT: DO NOT USE IF CARTON IS OPEN OR IF PRINTED SEAL ON BLISTER IS BROKEN OR MISSING.

INACTIVE INGREDIENT SECTION

LOINC: 51727-6Updated: 2/9/2022

Inactive ingredients

colloidal silicon dioxide, FD&C blue #2 aluminum lake, hypromellose, magnesium stearate, povidone.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Guaifenesin - FDA Drug Approval Details